{
    "Trade/Device Name(s)": [
        "EliA Gliadin IgA",
        "EliA Gliadin IgG",
        "EliA Celiac Control"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K063775",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MST",
        "JJY"
    ],
    "Summary Letter Date": "March 14, 2007",
    "Summary Letter Received Date": "February 13, 2007",
    "Submission Date": "February 12, 2007",
    "Regulation Number(s)": [
        "21 CFR 866.5750",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Radioallergosorbent (RAST) immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "IgA antibodies to gliadin",
        "IgG antibodies to gliadin",
        "Antibodies to tissue transglutaminase (tTG)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ImmunoCAP 100",
        "ImmunoCAP 250"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence immunoassay (FIA)",
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [
        "Solid phase immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for EliA Gliadin IgA, EliA Gliadin IgG, and EliA Celiac Control assays for the measurement of antibodies related to celiac disease using automated immunoassay analyzers.",
    "Indications for Use Summary": "Intended for the in vitro semi-quantitative measurement of IgA or IgG antibodies to gliadin in serum or plasma to aid in the diagnosis of celiac disease, and for laboratory use in monitoring assay performance using the ImmunoCAP 100 or 250 instruments.",
    "fda_folder": "Immunology"
}